Document Detail


Initial experience with bosentan therapy in patients with the Eisenmenger syndrome.
MedLine Citation:
PMID:  15246919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bosentan, an endothelin-1 antagonist that can be administered orally, has been shown to be effective in the treatment of idiopathic pulmonary arterial hypertension and may be of benefit to patients with the Eisenmenger syndrome. Nine patients with Eisenmenger's syndrome were treated with bosentan at a dose of 125 mg twice a day. After treatment with bosentan, 6 of 9 patients (67%) had an improvement in New York Heart Assocation classification of >/=1 grades (p = 0.03). Oxygen saturation levels increased from 79 +/- 5% to 88 +/- 6%, (p = 0.03). The side effects of bosentan therapy were minor; no significant changes in liver function tests were noted. These preliminary data suggest that oral administration of bosentan therapy for Eisenmenger's syndrome results in improved oxygenation and functional status with minimal side effects.
Authors:
Douglas D Christensen; Michael E McConnell; Wendy M Book; William T Mahle
Related Documents :
12446199 - Response to erythropoietin and moxifloxacin in a patient with myelodysplastic syndrome ...
18343329 - Burning mouth syndrome: recognition, understanding, and management.
19546439 - Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospect...
19690419 - Issues related to deep brain stimulation for treatment-refractory tourette's syndrome.
19560979 - Peroral endoscopic anastomotic reduction improves intractable dumping syndrome in roux-...
20086419 - Coping with patellofemoral syndrome.
15649819 - Mutations of brainstem transcription factors and central respiratory disorders.
2000359 - When to suspect connective tissue disease.
15383849 - Fast-track management of malignant superior vena cava syndrome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  94     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2004 Jul 
Date Detail:
Created Date:  2004-07-12     Completed Date:  2004-08-10     Revised Date:  2005-03-24    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  261-3     Citation Subset:  AIM; IM    
Affiliation:
Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antihypertensive Agents / therapeutic use*
Eisenmenger Complex / drug therapy*
Endothelin-1 / antagonists & inhibitors
Female
Humans
Male
Middle Aged
Retrospective Studies
Sulfonamides / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Sulfonamides; 147536-97-8/bosentan
Comments/Corrections
Comment In:
Am J Cardiol. 2005 Feb 1;95(3):435-6; author reply 436   [PMID:  15670566 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure.
Next Document:  Quality of life and social outcomes in adults with congenital heart disease living in rural areas of...